Michelle joined Quantum in December 2023 as a Principal Regulatory Strategist. She brings over 20 years of experience in regulatory strategy ranging from small start-ups to large multinational pharma with an emphasis on premarket strategy and development, both as an employee and as a consultant. Although she has supported programs across a variety of therapeutic areas, Michelle has a particular focus and expertise in the development of compounds for central nervous system disorders. Michelle is skilled at building personalized, collaborative, and enduring relationships with teams and takes a pragmatic approach to regulatory strategy.